Payment overview · 2025
General Payments
$13,252.30
33 reported records · 15 companies
Healthcare provider profile · identity verified
Derrick Wayne Scoggins, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BOWLING GREEN, KY · NPI 1053980540
Verified facts
What the public records show
CMS Open Payments records show Derrick Wayne Scoggins, APRN received $13,252.30 in general payments during 2025 across 33 reported records.
Tandem Diabetes Care, Inc. accounted for 97.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Jardiance, Kerendia, Ozempic, Rybelsus, Tymlos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Jardiance by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 543 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rybelsus by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $12,965.69 | 97.8% | 17 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $66.75 | 0.5% | 3 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $19.07 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.86 | 0.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.61 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.04 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.81 | 0.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.20 | 0.1% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $16.88 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.65 | 0.1% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $16.56 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.35 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.11 | 0.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.88 | 0.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.84 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,937.67 | 15 |
| Food and Beverage | $314.63 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $12,965.69 | 17 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $66.75 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 324 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 543 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 73 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | 35 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
324 | 80 |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
543 | 110 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 670 | 180 |
| Ozempic | Semaglutide | 543 | 110 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 383 | 109 |
| Jardiance | Empagliflozin | 324 | 80 |
| Mounjaro | Tirzepatide | 307 | 52 |
| Metformin Hcl | Metformin Hcl | 259 | 77 |
| Glimepiride | Glimepiride | 247 | 65 |
| Metformin Hcl Er | Metformin Hcl | 199 | 62 |
| Novolog Flexpen | Insulin Aspart | 156 | 54 |
| Farxiga | Dapagliflozin Propanediol | 150 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 42 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 143 | 50 |
| Trulicity | Dulaglutide | 132 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 125 | 48 |
| Humalog Kwikpen U-100 | Insulin Lispro | 116 | 41 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 106 | 34 |
| Methimazole | Methimazole | 100 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 99 | 27 |
| Humalog | Insulin Lispro | 99 | 30 |
| Novolog | Insulin Aspart | 94 | 25 |
| Simvastatin | Simvastatin | 92 | 26 |
| Losartan Potassium | Losartan Potassium | 88 | 29 |
| Synthroid | Levothyroxine Sodium | 87 | 35 |
| Tresiba Flextouch U-200 | Insulin Degludec | 87 | 23 |
| Glipizide | Glipizide | 85 | 25 |
| Insulin Lispro | Insulin Lispro | 77 | 19 |
| Kerendia | Finerenone | 76 | 19 |
| Ezetimibe | Ezetimibe | 73 | 16 |
| Rybelsus | Semaglutide | 73 | 19 |
| Januvia | Sitagliptin Phosphate | 68 | 23 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 67 | 24 |
| Lisinopril | Lisinopril | 64 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 51 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 47 | 20 |
| Vascepa | Icosapent Ethyl | 47 | suppressed |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 43 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 35 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 33 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 33 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | 12 |
| Atenolol | Atenolol | 32 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 28 | suppressed |
| Armour Thyroid | Thyroid,pork | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | 11 |
| Calcitriol | Calcitriol | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Furosemide | Furosemide | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Afrezza | Insulin Regular, Human | 18 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 13 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Omnipod 5 Dexg7g6 Intro(Gen 5) | Insulin Pmp Cart,aut,g6/7,cntr | 15 | 15 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tymlos | Abaloparatide | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 12 |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,252.30 · 33 records | Tandem Diabetes Care, Inc. | AFREZZA, ENTRESTO, EVENITY, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, MINIMED 780G, Ozempic, PROLIA, RECORLEV, Rybelsus, Tymlos, UBRELVY, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error